The stock of Enanta Pharmaceuticals Inc (ENTA) has seen a -15.36% decrease in the past week, with a 3.63% gain in the past month, and a 17.85% flourish in the past quarter. The volatility ratio for the week is 5.04%, and the volatility levels for the past 30 days are at 5.91% for ENTA. The simple moving average for the past 20 days is -12.18% for ENTA’s stock, with a 6.57% simple moving average for the past 200 days.
Is It Worth Investing in Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Right Now?
Moreover, the 36-month beta value for ENTA is 0.51. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ENTA is 19.65M and currently, short sellers hold a 13.96% of that float. On April 18, 2024, ENTA’s average trading volume was 244.42K shares.
ENTA) stock’s latest price update
Enanta Pharmaceuticals Inc (NASDAQ: ENTA)’s stock price has dropped by -8.85 in relation to previous closing price of 15.36. Nevertheless, the company has seen a loss of -15.36% in its stock price over the last five trading days. Seeking Alpha reported 2024-02-07 that Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
Analysts’ Opinion of ENTA
Many brokerage firms have already submitted their reports for ENTA stocks, with JP Morgan repeating the rating for ENTA by listing it as a “Underweight.” The predicted price for ENTA in the upcoming period, according to JP Morgan is $14 based on the research report published on August 09, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see ENTA reach a price target of $18, previously predicting the price at $49. The rating they have provided for ENTA stocks is “Hold” according to the report published on August 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to ENTA, setting the target price at $56 in the report published on December 09th of the previous year.
ENTA Trading at -4.34% from the 50-Day Moving Average
After a stumble in the market that brought ENTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.91% of loss for the given period.
Volatility was left at 5.91%, however, over the last 30 days, the volatility rate increased by 5.04%, as shares sank -0.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.18% upper at present.
During the last 5 trading sessions, ENTA fell by -15.36%, which changed the moving average for the period of 200-days by -34.58% in comparison to the 20-day moving average, which settled at $15.94. In addition, Enanta Pharmaceuticals Inc saw 48.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTA starting from Vance Terry, who sale 15,295 shares at the price of $9.12 back on Dec 13 ’23. After this action, Vance Terry now owns 5,800 shares of Enanta Pharmaceuticals Inc, valued at $139,490 using the latest closing price.
Luly Jay R., the President and CEO of Enanta Pharmaceuticals Inc, sale 7,230 shares at $9.63 during a trade that took place back on Dec 05 ’23, which means that Luly Jay R. is holding 806,793 shares at $69,625 based on the most recent closing price.
Stock Fundamentals for ENTA
Current profitability levels for the company are sitting at:
- -1.93 for the present operating margin
- 0.97 for the gross margin
The net margin for Enanta Pharmaceuticals Inc stands at -1.88. The total capital return value is set at -0.39. Equity return is now at value -56.11, with -35.63 for asset returns.
Based on Enanta Pharmaceuticals Inc (ENTA), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -3.63. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -64.06.
Currently, EBITDA for the company is -123.48 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 3.83. The receivables turnover for the company is 1.84for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.25.
Conclusion
To wrap up, the performance of Enanta Pharmaceuticals Inc (ENTA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
